OCMS Bio
OCMS Bio, LLC is an antibody discovery and engineering company focused on improving global patient health outcomes through rapid discovery and optimization of superior antibody drugs. The company leverages AI-driven drug discovery combined with its proprietary On-Cell mAb Screening (OCMS) platform to accelerate the identification and development of novel, de-risked, best-in-class antibodies optimized for binding, immunogenicity, stability, and function. OCMS Bio aims to address limitations in current antibody therapeutics related to dosing, administration, safety, and efficacy. The company has a strong scientific leadership team with extensive experience in biopharmaceutical development and antibody discovery, and it actively presents its research at industry conferences. OCMS Bio operates from a state-of-the-art facility in King of Prussia, Pennsylvania, and is expanding its preclinical pipeline with a focus on AI-driven antibody discovery.
OCMS Bio
OCMS Bio, LLC is an antibody discovery and engineering company focused on improving global patient health outcomes through rapid discovery and optimization of superior antibody drugs. The company leverages AI-driven drug discovery combined with its proprietary On-Cell mAb Screening (OCMS) platform to accelerate the identification and development of novel, de-risked, best-in-class antibodies optimized for binding, immunogenicity, stability, and function. OCMS Bio aims to address limitations in current antibody therapeutics related to dosing, administration, safety, and efficacy. The company has a strong scientific leadership team with extensive experience in biopharmaceutical development and antibody discovery, and it actively presents its research at industry conferences. OCMS Bio operates from a state-of-the-art facility in King of Prussia, Pennsylvania, and is expanding its preclinical pipeline with a focus on AI-driven antibody discovery.